All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Dynamics and persistence of CYP2D6 inhibition by paroxetine

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14740%2F13%3A00065968" target="_blank" >RIV/00216224:14740/13:00065968 - isvavai.cz</a>

  • Alternative codes found

    RIV/65269705:_____/13:#0002090

  • Result on the web

    <a href="http://onlinelibrary.wiley.com/doi/10.1111/jcpt.12042/abstract" target="_blank" >http://onlinelibrary.wiley.com/doi/10.1111/jcpt.12042/abstract</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1111/jcpt.12042" target="_blank" >10.1111/jcpt.12042</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Dynamics and persistence of CYP2D6 inhibition by paroxetine

  • Original language description

    What is known and Objective Paroxetine is both a substrate and an inhibitor of CYP2D6. The objective of the presented study was to determine the persistence of CYP2D6 inhibition after short term (6 weeks) and long term (18,7 +/- 10,6 weeks) paroxetine treatment. Methods: Two the studies consisted of 30 depressive/anxiety patients each. In the first study, patients were subdivided into three groups treated with paroxetine (A1), alprazolam (A2) and paroxetine + alprazolam (A3). After 6 weeks, all the patients (A1+A2+A3) were switched to alprazolam treatment; metabolic activity was evaluated at the beginning, after 6 weeks of paroxetine/alprazolam/alprazolam + paroxetine treatment (A1/A2/A3) and 4 weeks after the switch to alprazolam treatment (Week 0, 6,10). In the second study patients on previous long term paroxetine treatment were subdivided into two groups treated with mirtazapine (B1) or paroxetine (B2); metabolic activity of CYP2D6 was evaluated at the beginning and after 6 weeks

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

  • CEP classification

    FR - Pharmacology and apothecary chemistry

  • OECD FORD branch

Result continuities

  • Project

    Result was created during the realization of more than one project. More information in the Projects tab.

  • Continuities

    P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Others

  • Publication year

    2013

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

  • ISSN

    0269-4727

  • e-ISSN

  • Volume of the periodical

    38

  • Issue of the periodical within the volume

    4

  • Country of publishing house

    US - UNITED STATES

  • Number of pages

    7

  • Pages from-to

    294-300

  • UT code for WoS article

    000321339800006

  • EID of the result in the Scopus database